Search

Lee Gehrke Phones & Addresses

  • Cotuit, MA
  • Chestnut Hill, MA
  • Cambridge, MA
  • Chicago, IL
  • Plainfield, IL
  • Framingham, MA
  • Plainville, CT
  • Marstons Mills, MA
  • 58 Plympton St, Cambridge, MA 02138

Resumes

Resumes

Lee Gehrke Photo 1

Lee Gehrke

View page
Lee Gehrke Photo 2

Professor At Harvard University

View page
Location:
Greater Boston Area
Industry:
Higher Education
Experience:
Harvard University (Educational Institution; 10,001+ employees; Higher Education industry): Professor,  (-) 
Lee Gehrke Photo 3

Lee Gehrke

View page
Lee Gehrke Photo 4

Lee Gehrke

View page

Publications

Us Patents

Truncated Human Il-1 Cdna Sequences Which Encode Biologically-Active Human Il-1 Proteins

View page
US Patent:
50010573, Mar 19, 1991
Filed:
Apr 21, 1988
Appl. No.:
7/184211
Inventors:
Philip E. Auron - Framingham MA
Andrew C. Webb - Wellesley MA
Lee Gehrke - Framingham MA
Charles A. Dinarello - Boston MA
Lanny J. Rosenwasser - Weston MA
Alexander Rich - Cambridge MA
Sheldon M. Wolff - Wellesley MA
Assignee:
New England Medical Center - Boston MA
Tufts College - Boston MA
Wellesley College - Wellesley MA
MIT - Cambridge MA
International Classification:
C12P 2100
C12N 120
C12N 1500
C07H 2104
US Classification:
435 6952
Abstract:
The subject invention concerns truncated human IL-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.

Process For Enhancing Translational Efficiency Of Eukaryotic Mrna

View page
US Patent:
48206393, Apr 11, 1989
Filed:
Dec 4, 1985
Appl. No.:
6/804672
Inventors:
Lee Gehrke - Framingham MA
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
C12P 2100
C12P 1934
C12N 1500
US Classification:
435 68
Abstract:
A process and means for increasing the production of protein translated from eukaryotic messenger ribonucleic acid (mRNA) comprising transferring a regulatory nucleotide sequence from a viral coat protein mRNA to the 5' terminus of a gene or complementary deoxyribonucleic acid (cDNA) encoding the protein to be produced to form a chimeric DNA sequence. The regulatory DNA sequence are generated de novo using genetic engineering procedures to produce synthetic double-stranded oligonucleotides representing the regulatory viral sequence. Nucleotide sequences which encode a regulatory sequence or structure conferring enhanced competitive activity and increased rate of translation upon the chimeric DNA sequences include the nucleotide sequence preceding the initiator AUG codon at the 5' terminus of coat protein messenger RNA from alfalfa mosaic virus, brome mosaic virus, black beetle virus, turnip yellow mosaic virus, and satellite tobacco necrosis virus.

Interleukin-1 Muteins, Their Preparation And Method Of Use To Inhibit Interleukin-1 Activity

View page
US Patent:
52868478, Feb 15, 1994
Filed:
May 19, 1992
Appl. No.:
7/887118
Inventors:
Lee Gehrke - Framingham MA
Philip E. Auron - Ashland MA
Lanny Rosenwasser - Weston MA
Assignee:
New England Medical Center Hospitals, Inc. - Boston MA
Massachusetts Institute of Technology - Cambridge MA
International Classification:
C07K 1300
US Classification:
530351
Abstract:
Disclosed are novel muteins of IL-1 compounds which can be used to regulate excess IL-1 produced in various diseases in humans and animals. The IL-1 muteins can be prepared by site-directed mutagenesis whereby a positively charged residue is replaced with a negatively charged or neutral residue at a designated position in the molecule. The resulting IL-1 muteins have reduced biological activity but retain receptor binding affinity.

Modified Transcriptionally Active Sp6 Plasmid Vector

View page
US Patent:
49487310, Aug 14, 1990
Filed:
Aug 5, 1986
Appl. No.:
6/893482
Inventors:
Lee Gehrke - Framingham MA
Robert T. Fraley - St. Louis MO
Stephen G. Rogers - Chesterfield MO
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
C12N 100
C12N 1500
C12N 122
C12N 120
C12P 1934
C12P 1206
C07H 1512
US Classification:
435 91
Abstract:
A recombinant plasmid which may be used for propagation of cloned cDNAs and also for the in vitro synthesis of RNA which is an exact copy of the natural sequence, wherein the transcript is devoid of vector-derived sequence. The novel vector was generated de novo by genetic engineering procedures using a synthetic double strand oligodeoxyribonucleotide fragment and a larger DNA fragment derived from plasmid pSP64. The vector, plasmid pHST-O, carried by Escherichia coli HB101, deposited with the ATCC on Dec. 30, 1985 and designated ATCC 53381, is distinguished from other vectors containing the SP6 promoter by the following characteristics: it contains a unique site for the restriction endonuclease BglII; the engineered GBlII site overlaps the downstream border of the SP6 promoter sequence; and the presence and positioning of the BglII restriction site permit insertion of cDNA molecules in such a way that transcription by the SP6 RNA polymerase begins exactly at the 5' terminus of the RNA, providing that the 5' terminal nucleotide of the mRNA transcript is a guanosine (G) residue, thus excluding the transcription of nucleotides derived from the vector. The novel vector permits synthesis of RNA molecules which have a defined 5' terminus and which are devoid of vector-derived sequence. The vector has potential use in research in molecular biology and in the in vitro production of RNA and proteins.

Truncated Protein Of Interleukin-1

View page
US Patent:
47629142, Aug 9, 1988
Filed:
Feb 11, 1985
Appl. No.:
6/700374
Inventors:
Philip E. Auron - Framingham MA
Andrew C. Webb - Wellesley MA
Lee Gehrke - Framingham MA
Charles A. Dinarello - Boston MA
Lanny J. Rosenwasser - Weston MA
Alexander Rich - Cambridge MA
Sheldon M. Wolff - Wellesley MA
International Classification:
C07K 1300
US Classification:
530351
Abstract:
The subject invention concerns truncated human IL-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.

Human Il-1 Cdna Sequences Encoding Biologically-Active Human Il-1 Proteins

View page
US Patent:
50772198, Dec 31, 1991
Filed:
Aug 21, 1990
Appl. No.:
7/570069
Inventors:
Philip E. Auron - Framingham MA
Andrew C. Webb - Wellesley MA
Lee Gehrke - Framingham MA
Charles A. Dinarello - Boston MA
Lanny J. Rosenwasser - Weston MA
Alexander Rich - Cambridge MA
Sheldon M. Wolff - Wellesley MA
Assignee:
New England Medical Center Hospitals - Boston MA
Wellesley College - Wellesley MA
Tufts College - Boston MA
MIT - Cambridge MA
International Classification:
C12N 1500
C12N 1511
US Classification:
4353201
Abstract:
The subject invention concerns truncated human Il-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.

Anti-Dengue Virus Ns1 Protein Monoclonal Antibodies

View page
US Patent:
20200363415, Nov 19, 2020
Filed:
Dec 9, 2019
Appl. No.:
16/707508
Inventors:
- Cambridge MA, US
- Silver Spring MD, US
Jose Gomez-Marquez - Cambridge MA, US
Helena dePuig Guixe - Cambridge MA, US
Lee Gehrke - Cotuit MA, US
International Classification:
G01N 33/569
C07K 16/10
Abstract:
The present invention provides matched antibody pairs for the specific detection of one or more of the four dengue virus serotypes in a biological sample that may contain one or more of such dengue virus serotypes. Each matched antibody pair is capable of detecting not more than one serotype of dengue virus NS1 protein that may be present in the sample and will not cross react with other serotypes that may be present in the sample. Multiple matched pairs may be used to detect one or more dengue virus serotypes that may be present in a sample. Such matched pair antibodies, facilitate the development of confirmatory in vitro diagnostic tests such as sandwich immunoassays, that detect and distinguish the presence of one or more dengue virus serotypes in a biological sample, preferably a sample derived from human subject. The invention also provides kits comprising the matched antibody pairs of the invention and methods for using the kits for immunoassays for the specific detection of one or more serotypes of dengue virus in a patient population. The present invention also provides monoclonal antibodies specific for the NS1 protein of dengue virus and therapeutic compositions and methods for treating dengue virus infection.

Anti-Dengue Virus Ns1 Protein Monoclonal Antibodies

View page
US Patent:
20170233460, Aug 17, 2017
Filed:
Feb 10, 2017
Appl. No.:
15/429756
Inventors:
- Cambridge MA, US
Jose Gomez-Marquez - Boston MA, US
Helena de Puig - Cambridge MA, US
Lee Gehrke - Cotuit MA, US
International Classification:
C07K 16/10
G01N 33/569
Abstract:
The present invention provides matched antibody pairs for the specific detection of one or more of the four dengue virus serotypes in a biological sample that may contain one or more of such dengue virus serotypes. Each matched antibody pair is capable of detecting not more than one serotype of dengue virus NS1 protein that may be present in the sample and will not cross react with other serotypes that may be present in the sample. Multiple matched pairs may be used to detect one or more dengue virus serotypes that may be present in a sample. Such matched pair antibodies, facilitate the development of confirmatory in vitro diagnostic tests such as sandwich immunoassays, that detect and distinguish the presence of one or more dengue virus serotypes in a biological sample, preferably a sample derived from human subject. The invention also provides kits comprising the matched antibody pairs of the invention and methods for using the kits for immunoassays for the specific detection of one or more serotypes of dengue virus in a patient population. The present invention also provides monoclonal antibodies specific for the NS1 protein of dengue virus and therapeutic compositions and methods for treating dengue virus infection.
Lee Roy Gehrke from Cotuit, MA, age ~72 Get Report